PPIs may affect responses to atezolizumab in patients with urothelial cancer

(American Association for Cancer Research) Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with urothelial cancer treated with the immunotherapeutic atezolizumab (Tecentriq), compared with patients who did not use PPIs.